Mapi Posters

2017. EAN Congress – The role of clinical outcome assessment (COA) data in the drug approval process of medicines for the treatment of restless legs syndrome (RLS): A review of the labels of medicines approved by the FDA and the EMA

Emery MP, Anfray C, Perrier LL, Acquadro C. The role of clinical outcome assessment (COA) data in the drug approval process of medicines for the treatment of restless legs syndrome (RLS): A review of the labels of medicines approved by the FDA and the EMA. Eur J Neurol. 2017;24(Suppl.1):177. Presented at: EAN 2017; June 24-27, 2017; Amsterdam, The Netherlands.